SCHEMBL20239176

SCHEMBL20239176

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)nc(SC)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.55
KDM4E B2RXH2 1/20 0.35
LMNA P02545 4/20 0.35
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTT P42858 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MAPT P10636 5/20 0.34
L3MBTL1 Q9Y468 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
RECQL P46063 1/20 0.34
MAPK1 P28482 2/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA7 P43166 2/20 0.32
CA13 Q8N1Q1 2/20 0.32
VNN1 O95497 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738674 0.90 DGAT2 (0.57) DGAT2KDM4ELMNAHTTSMN1; SMN2
SCHEMBL20239203 0.87 DGAT2 (0.59) DGAT2KDM4ELMNASMN1; SMN2MEN1
SCHEMBL20239333 0.87 DGAT2 (0.56) DGAT2KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20239227 0.86 DGAT2 (0.56) DGAT2KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20239171 0.86 DGAT2 (0.56) DGAT2KDM4ELMNAHTTSMN1; SMN2
SCHEMBL21985553 0.84 DGAT2 (0.49) DGAT2LMNATSHRNPSR1HTT
SCHEMBL20239169 0.84 DGAT2 (0.54) DGAT2KDM4ELMNASMN1; SMN2MAPT
SCHEMBL18249757 0.84 DGAT2 (0.54) DGAT2KDM4ELMNAHTTSMN1; SMN2
SCHEMBL20239272 0.84 DGAT2 (0.55) DGAT2KDM4ESMN1; SMN2VNN1CYP3A4
SCHEMBL20239148 0.81 LMNA (0.41) DGAT2KDM4ELMNATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885LMNA 2022/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885LMNA 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.